Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s Perjeta shows survival benefits for breast cancer patients

Roche’s Perjeta shows survival benefits for breast cancer patients

1st October 2014

Roche has announced data from the phase III study CLEOPATRA, which shows the survival benefits breast cancer patients can receive from treatment with Perjeta.

Adding Perjeta to Herceptin and docetaxel chemotherapy was shown to extend overall survival among people with previously untreated HER2-positive metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy alone.

The median overall survival rate of almost five years was the longest observed to date in people with this aggressive type of advanced breast cancer, while no new safety signals were observed.

Data from the study will support the company's efforts to secure regulatory approval for use of the regimen pre-surgery in the US and Europe.

Dr Sandra Horning, Roche's chief medical officer and head for global product development, described the findings as representing "a magnitude of improvement we rarely see in clinical trials in advanced cancer".

The drug was approved in Europe last year and went on sale in the UK in March 2013.ADNFCR-8000103-ID-801751922-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.